CANCER IMMUNOLOGY PROGRAM AREA REPORT
October 1, 1977 to September 30, 1978
| Program Coordinators: | Dr. Yohei Ito Dr. Robert McAllister |
| Monday, September 25 TUMOR ASSOCIATED IMMUNITY |
||
| 8:45 a.m. | Introductory Comments | Yuichi Yamamura William Terry |
| 9:05 a.m. | In Vitro Introduction of Tumor Specific Immunity | Noel Warner |
| 9:40 a.m. | The Cellular Basis of Cytotoxic T Cell Responses to Tumors | Chris Henney |
| 10:15 a.m. | Characterization of ADCC in Man | Albert LoBuglio |
| 10:50 a.m. | COFFEE BREAK | |
| 11:05 a.m. | Cell Mediated Cytotoxic Responses to Human Melanoma Target Cells | Michael Bean |
| 11:40 a.m. | Serological Typing of Cell Surface Antigens of Human Malignant Melanoma | Toshitada Takahashi |
| 12:15 p.m. | Serological Typing of Cell Surface Antigens of Human Renal Cancer and Astrocytoma | Hiroshi Shiku |
| CHARACTERIZATION OF IMMUNE CELLS | ||
| 7:30 p.m. | Expression of I Region Gene Products on Accessory Cell Populations | Richard Hodes |
| 8:05 p.m. | Distribution of T and B Cells in Cancer Tissues | Kokichi Kikuchi |
| 8:40 p.m. | Characterization of Murine T and B Cell Lymphomas Through Quantitative Analysis of Cell Surface Marker Expression | Noel Warner |
Tuesday, September 26 SUPPRESSION OF IMMUNE RESPONSES |
||
| 8:30 a.m. | Selective Stimulation and Inactivation of Suppressor T Cells in Tumor Immunology | Tomio Tada |
| 9:05 a.m. | Suppressor T Cells and Suppressor Macrophages: Their Induction and a Comparison of their Mechanism of Action | Chris Henney |
| 9:40 a.m. | Suppressor Cells in Ultraviolet Carcinogenesis | Richard Thorn |
| 10:15 a.m. | COFFEE BREAK | |
| 10:30 a.m. | Restricted Suppressor T Cell Activity in the Blood of a Patient with Recurrent Bladder Carcinoma | Michael Bean |
| 11:05 a.m. | Suppressor Cells in Tumor Bearing Individuals | Ronald Herberman |
| MACROPHAGES | ||
| 11:40 a.m. | Studies on the Role of Oxidative Metabolism in the Tumor Cell Cytotoxicity of Activated Macrophages | Carl Nathan |
| 12:15 p.m. | Activation of Tumoricidal Macrophages with Lymphokines | Toru Tokunaga |
| NATURAL KILLER CELLS | ||
| 7:30 p.m. | Natural Killer Cells: Their Mechanism of Action and Possible Significance in Neoplasia | Chris Henney |
| 8:05 p.m. | Natural Cell Mediated Cytotoxicity Against Tumors: Nature of Effector Cells and Factors Affecting Activity | Ronald Herberman |
| 8:40 p.m. | Approaches to the Identification of the Natural Killer Cell and its Target Cell Specificity | Noel Warner |
| 9:15 p.m. | Active Immunization With Xenogenized Tumor Cells | Hiroshi Kobayashi |
Wednesday, September 27 PRECLINICAL IMMUNOTHERAPY |
||
| 8:30 a.m. | Immunotherapy of Cancer With Nocardia Rubra Cell Wall Skeleton | Yuichi Yamamura |
| 9:05 a.m. | Synthetic Immunotherapeutic Agents | Ichiro Azuma |
| PRECLINICAL IMMUNOTHERAPY | ||
| 9:40 a.m. | Specific Immunotherapy of Established Visceral Micro-metastases by BCG Tumor Cell | Michael Hanna |
| 10:15 a.m. | COFFEE BREAK | |
| 10:30 a.m. | Experimental Immunotherapy of Cancer With Cell-Wall Skeletons of BCG and Nocardia Rubra | Takeshi Ogura |
| 11:05 a.m. | Correlation Between Antigenicity of Cancer Cells and Therapeutic Effect of Immunopotentiators | Yoshiyuki Hashimoto |
| 11:40 a.m. | Treatment of Established Micrometastases by Injection of Tumoricidal Macrophages | |
| CLINICAL IMMUNOTHERAPY | ||
| 1:30 p.m. | The Immunotherapy of Acute Myelogenous Leukemia Using Cell-Wali Skeletons of BCG and Nocardia Rubra | Kazuhisa Yamada |
| 2:05 p.m. | Preoperative Intralesional BCG Immunotherapy of Lung Cancer | E. Carmack Holmes |
| 2:40 p.m. | Immunotherapy of Lung Cancer With the Cell-Wall Skeletons of BCG and Nocardia Rubra | Kenji Sawamura |
| Tuesday, June 6 | ||
| 9:00 a.m. | Opening Remarks | H. Kobayashi |
| 9:05 a.m. | Opening Remarks | C. W. Boone |
| Session 1A: Xenogenization with Virus Co-chairmen: G. J. Svet-Moldavsky and J. Lindenmann |
||
| 9:15 a.m. | Xenogenization by Viruses: How Could it Work? | J. Lindenmann |
| 9:55 a.m. | Augmented TATA Immunogenecity of Membranous and Soluble Extracts frorn Tumor Cells Infected with Surface Budding Virus | C. W. Boone |
| 10:35 a.m. | COFFEE BREAK | |
| 10:50 a.m. | Artificial Heterogenization (Xenogenization) of Tumors | G. J.Svet-Moldavsky |
| 11:30 a.m. | Immunogenicity of Virus-Infected Xenogenized Tumor Cells | H. Kobayashi and F. Sendo |
| 12:10 p.m. | Increased Immunogenicity of Rat Tumors After Infection With Endogenous Murine C-type Virus | N. Kuzumaki and C. Klein |
| Session 1B: Xenogenization with Virus Co-chairmen: C. W. Boone and H. Uetake |
||
| 2:00 p.m. | Stabilized Expression of Tumor-Associated Antigen in Xenogenized Tumor Cells to Complement Dependent Cytotoxicity | E. Cotohda and T. Kodama |
| 2:40 p.m. | The Role of Virus-Associated Antigen on Xenogenized Tumor Cell Surface in Production of Antibody Against Tumor-Associated Antigen | T. Moriuchi |
| 3:10 p.m. | Increased Immunosensitivity of Xenogenized Tumor Cells to Lymphocyte Cyiotoxicity | M. Hosokawa |
| 3:50 p.m. | COFFEE BREAK | |
| 4:10 p.m. | Induction of Immune resistance by HVJ-infected L1210 Cells | K. Yamada |
| 4:50 p.m. | Decreased Transplantability of Cultured Tumor Cells Persistently Infected with Nononcogenic Viruses | M. Hatano |
| 5:20 p.m. | Breakdown of MuL V-Induced Tolerance and Subsequent Regression of Xenogenized Tumors | N. Takeichi |
Wednesday, June 7 Session 2A: Xenogenization with Chemicals and Enzymes Co-chairmen: C. M. Shearer and Y. Hashimoto |
||
| 9:00 a.m. | Enhanced Immunogenecity of Concanavalin A Coated Tumor Cells | W. J. Martin |
| 9:40 a.m. | Induction of Immune Resistance to L1210 Murine Leukernia by Lectin-Bound Tumor Vaccine | T. Kataoka |
| 10:00 a.m. | Induction of Immune Resistance Against Tumor in a Low Responsive Tumor-Host Combination by Immunization With Chemically Modified Tumor Cells in the Presence of the Chemicals-Reactive Helper T Cells | T. Hamaoka |
| 10:40 a.m. | COFFEE BREAK | |
| 10:55 a.m. | Induction of Immunity with Fluorescence-Haptenized Tumor Cells and Liposomes | Y. Hashimoto |
| 11:20 a.m. | Immunoprophylaxis and Therapy With Lipid Conjugated Lymphoma Cells | M. D. Prager |
| 12:00 noon | Alteration of Immunosensitivity in Nitrogen Mustard-Resistant Yoshida Sarcoma Cells | S. Tsukagoshi |
| Session 2B: Recognition of Cell Surface Antigens Undergoing Xenogenization Co-chairmen: N. A. Mitchison and T. Tada |
||
| 2:00 p.m. | Non-Enveloped Virus-Induced Specific Cell Surface Antigen(s) and Its Role in Cell-Mediated Immunity | H. Uetake, T. Inada, and S. Hasegawa |
| 2:30 p.m. | Development and Alternate Changes of Surface Antigen in Adenovirus Type 12-Infected and Transformed Cells | C. Hamada |
| 2:50 p.m. | MHC-Restriction of T-Cell Recognition | R. M. Zinkcrnagel |
| 3:30 p.m. | COFFEE BREAK | |
| 3:45 p.m. | Associate Recognition in the Response to Allo-Antigens (and Xenogenization of Allo-Antigens) | N. A. Mitchison |
| 4:25 p.m. | Differential Recognition of Tumor Antigens by Cyto-toxic and Suppressor T Cells | T. Tada |
| 5:00 p.m. | Recognition of RSV-Induced Tumor Cells in Syngeneic Mice and Semi-Syngeneic Reciprocal Hybrid Mice | Takato Yoshida |
| 5:20 p.m. | Genetic Regulation of Immune Responses to TNP-Modified Cells | C. M. Shearer |
Thursday, June 8 Session 3A: Xenogenization by Cell-Hybridization Co-chairmen: A. J. S. Davies and T. Tachibana |
||
| 9:00 a.m. | Antigenic Expression on Somatic Cell Hybrids in Relation to the Potential Use of Hybridization for Tumor Xenogenization | C. Klein |
| 9:40 a.m. | Antigenic Expression on Mouse Hybrid Cells | T. Tachibana |
| 10:20 a.m. | COFFEE BREAK | |
| 10:35 a.m. | Immune Response to Hybrid Cells in Normal and Tumor-Bearing Mice | T. Dei |
| 11:15 a.m. | Liposomal Fusion as a Means of Introducing Surface Antigens Into Living Cell Membranes | A. J. S. Davies |
| 11:55 a.m. | Open Discussion | |
| Session 3B: Application of Xenogenization to Human Cancer Co-chairmen: G. Klein and T. Aoki |
||
| 2:00 p.m. | Melanoma Skin Test Antigens of Improved Sensitivity Prepared from Vesicular Stomatitis Virus-Infected Tumor Cells | C. W. Boone |
| 2:30 p.m. | Vaccinia Virus Augmented Tumor Vaccine as a New Form of Immunotherapy. | M. K. Wallack |
| 3:00 p.m. | COFFEE BREAK | |
| 3:15 p.m. | Attempts at Virus-Associated Immunotherapy in Human Cancer | J. Lindenmann |
| 3:45 p.m. | Oncotropic Viruses and Problems in Virotherapy | A. J. Muceniece |
| 10:00 a.m. | Regulation of the Immune Response by la-Antigen Complexes | Chairman: M. Aizawa Speaker: N. A. Mitchison (UK) |
| 10:40 a.m. | Derepressed Histocompatibility Alloantigen on Transplacentally Induced Murine Lung Tumors | Chairman: F. Sendo Speaker: W. J. Martin (USA) |
| 11:20 a.m. | Long-Term Studies of the Lymphoid System of the Mouse | Chairman: K. Kikuchi Speaker: A. J. S. Davies (UK) |
| 1:30 p.m. | Immune Response, Protection and Autoimmunity Following Immunization of Mice With Modified Syngeneic Tumor Cells | Chairman: H. Hosokawa Speaker: M. D. Prager (USA) |
| 2:10 p.m. | Paradoxical Age-Dependent Features of Growth of Transplanted Fetal Tissues and Tumors | Chairman: H. Kobayashi Speaker: G. Svet-Modavsky (USSR) |
| 2:50 p.m. | Spontaneous Neoplastic Transformation in vitro and its Relationship to Plastic Film Tumorigenesis | Chairman: M. Sasaki Speaker: C. W. Boone (USA) |
| 3:30 p.m. | Oncolytic Enteroviruses in Experiment and Clinics | Chairman: T. Kodama Speaker: A. J. Muceniece (USSR) |
| 4: 10 p.m. | Adjuvant Therapy of Carcinoma of the Colon and Rectum with Vaccinia Oncolysates | Chairman: T. Tanabe Speaker: M. K. Wallack (USA) |